Candel Therapeutics (CADL) EBT Margin (2020 - 2022)
Candel Therapeutics (CADL) posted EBT Margin of 28925.81% for Q4 2022, up 0.99% sequentially from 29216.13% in Q3 2022, and up 40580753.0% YoY from N/an in Q4 2021.
Candel Therapeutics (CADL) EBT Margin (2020 - 2022) Analysis & Trends
Candel Therapeutics has reported EBT Margin for 3 years, with the latest figure at 28925.81% in Q4 2022.
- Quarterly EBT Margin rose 40580753.0% year-over-year to 28925.81% in Q4 2022, while the trailing twelve-month figure through Dec 2022 was 52656.45% (down 824534.0% YoY) and the FY2022 annual result came in at 51072.0%, down 2900.0% from the prior year.
- EBT Margin improved to 28925.81% in Q4 2022 per CADL's latest filing, from 29216.13% in the prior quarter.
- Over five years, EBT Margin peaked at 7458.06% in Q2 2020 and troughed at 434733.33% in Q4 2021.
- A 3-year average of 70501.56% and a median of 28925.81% in 2022 frame the typical range for EBT Margin.
- The sharpest annual moves came in 2021 and 2022: EBT Margin sank 37860108 bps in 2021, then soared 40580753 bps in 2022.
- Over 3 years, EBT Margin stood at 56132.26% in 2020, then plunged by 674 bps to 434733.33% in 2021, then soared by 93 bps to 28925.81% in 2022.
- According to Business Quant data, EBT Margin over the past three periods registered 28925.81%, 29216.13%, and 29412.9% for Q4 2022, Q3 2022, and Q2 2022 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 34.77% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 18.33% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -94.22% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.77% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -2.67% |
| 10 | Candel Therapeutics | 643.41 Mn | 643.41 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | -28,925.81% |
| Sep 30, 2022 | -29,216.13% |
| Jun 30, 2022 | -29,412.90% |
| Mar 31, 2022 | -123,070.97% |
| Dec 31, 2021 | -434,733.33% |
| Sep 30, 2021 | -25,477.42% |
| Jun 30, 2021 | -17,148.39% |
| Mar 31, 2021 | -15,061.29% |
| Dec 31, 2020 | -56,132.26% |
| Sep 30, 2020 | -8,880.65% |
| Jun 30, 2020 | -7,458.06% |